NCT05836324

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 408 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

Conditions

• Solid Tumors
• Advanced Solid Tumors
• Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	INCA33890	INCA33890 will be administered at protocol defined dose.
DRUG	bevacizumab	Bevacizumab will be administered at protocol defined dose.
DRUG	FOLFIRI	FOLFIRI will be administered at protocol defined dose.
DRUG	FOLFOX	FOLFOX will be administered at protocol defined dose.
DRUG	Cetuximab	Cetuximab will be administered at protocol defined dose.

Timeline

• Start date: 2023-07-24
• Primary completion: 2027-01-13
• Completion: 2027-01-13
• First posted: 2023-05-01
• Last updated: 2025-12-18

Locations

36 sites across 8 countries: United States, Denmark, France, Italy, Japan, Spain, Switzerland, United Kingdom

Regulatory

• FDA-regulated drug study